CHARACTERIZATION AND APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS IN RISK ASSESSMENT

The overall objectives of the IPCS are to establish the scientific basis for assessment of the risk to human health and the environment from exposure to chemicals, through international peer review processes, as a prerequisite for the promotion of chemical safety, and to provide technical assistance in strengthening national capacities for the sound management of chemicals. (Participating Organizations), following recommendations made by the 1992 UN Conference on Environment and Development to strengthen cooperation and increase coordination in the field of chemical safety. The purpose of the IOMC is to promote coordination of the policies and activities pursued by the Participating Organizations, jointly or separately, to achieve the sound management of chemicals in relation to human health and the environment. WHO Library Cataloguing-in-Publication Data Characterization and application of physiologically based pharmacokinetic models in risk assessment. e-mail: bookorders@who.int). Requests for permission to reproduce or translate WHO publications—whether for sale or for non-commercial distribution—should be addressed to WHO Press at the above address (fax: +41 22 791 4806; e-mail: permissions@who.int). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

[1]  D Krewski,et al.  Uncertainty, variability, and sensitivity analysis in physiological pharmacokinetic models. , 1995, Journal of biopharmaceutical statistics.

[2]  H J Clewell,et al.  Evaluation of the uncertainty in an oral reference dose for methylmercury due to interindividual variability in pharmacokinetics. , 1999, Risk analysis : an official publication of the Society for Risk Analysis.

[3]  R A Corley,et al.  Physiologically based pharmacokinetics of 2-butoxyethanol and its major metabolite, 2-butoxyacetic acid, in rats and humans. , 1994, Toxicology and applied pharmacology.

[4]  M E Andersen,et al.  Mode-of-action-based dosimeters for interspecies extrapolation of vinyl acetate inhalation risk. , 2001, Inhalation toxicology.

[5]  M E Meek,et al.  Assessing the dose-dependency of allometric scaling performance using physiologically based pharmacokinetic modeling. , 2003, Regulatory toxicology and pharmacology : RTP.

[6]  H J Clewell,et al.  Applying simulation modeling to problems in toxicology and risk assessment--a short perspective. , 1995, Toxicology and applied pharmacology.

[7]  Timothy R. Gerrity,et al.  Principles of route-to-route extrapolation for risk assessment : proceedings of the Workshops on Principles of Route-to-Route Extrapolation for Risk Assessment held March 19-21, 1990, in Hilton Head, South Carolina and July 10-11, 1990, in Durham, North Carolina , 1990 .

[8]  H J Clewell,et al.  Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene. , 1995, Chemosphere.

[9]  F Y Bois,et al.  Statistical analysis of Fisher et al. PBPK model of trichloroethylene kinetics. , 2000, Environmental health perspectives.

[10]  Malcolm Rowland,et al.  Mechanistic Approaches to Volume of Distribution Predictions: Understanding the Processes , 2007, Pharmaceutical Research.

[11]  I. Nestorov,et al.  Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. , 2001, Toxicology letters.

[12]  Edward Ohanian,et al.  Toxicokinetics and Risk Assessment , 2006 .

[13]  P. Watanabe,et al.  Resolution of dose-response toxicity data for chemicals requiring metabolic activation: example--vinyl chloride. , 1978, Toxicology and applied pharmacology.

[14]  J. Dorne,et al.  Uncertainty factors for chemical risk assessment: interspecies differences in glucuronidation. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[15]  Malcolm Rowland,et al.  Reducing Whole Body Physiologically Based Pharmacokinetic Models Using Global Sensitivity Analysis: Diazepam Case Study , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  Richard A Corley,et al.  Evaluation of Physiologically Based Models of Pregnancy and Lactation for Their Application in Children's Health Risk Assessments , 2003, Critical reviews in toxicology.

[17]  M Rowland,et al.  Physiologic pharmacokinetic models and interanimal species scaling. , 1985, Pharmacology & therapeutics.

[18]  Harvey J Clewell,et al.  A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. , 2001, Environmental health perspectives.

[19]  K Walton,et al.  Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[20]  Hugh A Barton,et al.  Evaluation of physiologically based pharmacokinetic models for use in risk assessment , 2007, Journal of applied toxicology : JAT.

[21]  H J Clewell,et al.  Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans. , 1991, Toxicology and applied pharmacology.

[22]  G. Johanson,et al.  Gas chromatographic determination of butoxyacetic acid in human blood after exposure to 2-butoxyethanol , 2005, Archives of Toxicology.

[23]  Alan R. Boobis,et al.  IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans , 2008, Critical reviews in toxicology.

[24]  M L Dourson,et al.  Evolution of science-based uncertainty factors in noncancer risk assessment. , 1996, Regulatory toxicology and pharmacology : RTP.

[25]  M. Zeilmaker,et al.  Application of physiologically based pharmacokinetic modeling in setting acute exposure guideline levels for methylene chloride. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[26]  F Y Bois,et al.  Statistical analysis of Clewell et al. PBPK model of trichloroethylene kinetics. , 2000, Environmental health perspectives.

[27]  F. A. Smith,et al.  Physiologically based pharmacokinetics and the risk assessment process for methylene chloride. , 1987, Toxicology and applied pharmacology.

[28]  S. Haddad,et al.  A Physiologically Based Pharmacokinetic Model for the Assessment of Infant Exposure to Persistent Organic Pollutants in Epidemiologic Studies , 2008, Environmental health perspectives.

[29]  G. E. Searle,et al.  APPLICATION OF A GENERIC PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL TO THE ESTIMATION OF XENOBIOTIC LEVELS IN RAT PLASMA , 2006, Drug Metabolism and Disposition.

[30]  R B Conolly,et al.  Physiologically based pharmacokinetic models applicable to organogenesis: extrapolation between species and potential use in prenatal toxicity risk assessments. , 1995, Toxicology letters.

[31]  Carolyn Vickers,et al.  IPCS framework for analysing the relevance of a cancer mode of action for humans , 2006 .

[32]  John C Lipscomb,et al.  Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. , 2007, Current drug metabolism.

[33]  A. Saltelli,et al.  Sensitivity analysis of an environmental model: an application of different analysis methods , 1997 .

[34]  George Loizou,et al.  Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. , 2008, Regulatory toxicology and pharmacology : RTP.

[35]  B. Allen,et al.  Evaluation of uncertainty in input parameters to pharmacokinetic models and the resulting uncertainty in output. , 1989, Toxicology letters.

[36]  Walter Schmitt,et al.  General approach for the calculation of tissue to plasma partition coefficients. , 2008, Toxicology in vitro : an international journal published in association with BIBRA.

[37]  R L Dedrick,et al.  Species similarities in pharmacokinetics. , 1980, Federation proceedings.

[38]  R. Lutz,et al.  Transport and binding of methotrexate in vivo. , 1973, Journal of pharmaceutical sciences.

[39]  G. Johanson,et al.  Physiologically based modeling of the inhalation kinetics of styrene in humans using a bayesian population approach. , 2002, Toxicology and applied pharmacology.

[40]  G. Johanson,et al.  A Bayesian analysis of the influence of GSTT1 polymorphism on the cancer risk estimate for dichloromethane. , 2001, Toxicology and applied pharmacology.

[41]  W Veerkamp,et al.  Fate and exposure models in relation to risk assessment , 1996, Environmental science and pollution research international.

[42]  M C Kohn,et al.  Achieving credibility in risk assessment models. , 1995, Toxicology letters.

[43]  K Walton,et al.  Pathway-Related Factors: The Potential for Human Data to Improve the Scientific Basis of Risk Assessment , 2001 .

[44]  K Walton,et al.  Default Factors for Interspecies Differences in the Major Routes of Xenobiotic Elimination , 2001 .

[45]  Ewart R. Carson,et al.  The mathematical modeling of metabolic and endocrine systems : model formulation, identification, and validation , 1983 .

[46]  M E Andersen,et al.  A biologically based risk assessment for vinyl acetate-induced cancer and noncancer inhalation toxicity. , 1999, Toxicological sciences : an official journal of the Society of Toxicology.

[47]  Paul S Price,et al.  Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans , 2003, Critical reviews in toxicology.

[48]  M E Andersen,et al.  Mode of action and tissue dosimetry in current and future risk assessments. , 2001, The Science of the total environment.

[49]  John C Lipscomb,et al.  In vitro measurements of metabolism for application in pharmacokinetic modeling. , 2008, Pharmacology & therapeutics.

[50]  M. Andersen,et al.  Risk Assessment Extrapolations and Physiological Modeling , 1985, Toxicology and industrial health.

[51]  Edward V. Sargent,et al.  Case Studies of Categorical Data-Derived Adjustment Factors , 2001 .

[52]  H. Barton,et al.  Evaluating human variability in chemical risk assessment: hazard identification and dose-response assessment for noncancer oral toxicity of trichloroethylene. , 1996, Toxicology.

[53]  Cindy Sonich-Mullin,et al.  Practical application of kinetic data in risk assessment--an IPCS initiative. , 2003, Toxicology letters.

[54]  M Younes,et al.  IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. , 2001, Regulatory toxicology and pharmacology : RTP.

[55]  Melvin E. Andersen,et al.  Physiologically Based Pharmacokinetic Modeling , 2010 .

[56]  N Oreskes,et al.  Evaluation (not validation) of quantitative models. , 1998, Environmental health perspectives.

[57]  K Walton,et al.  Species-specific uncertainty factors for compounds eliminated principally by renal excretion in humans. , 2004, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[58]  M E Andersen,et al.  Tissue dosimetry, pharmacokinetic modeling, and interspecies scaling factors. , 1995, Risk analysis : an official publication of the Society for Risk Analysis.

[59]  J W Fisher,et al.  In vitro to in vivo extrapolation for trichloroethylene metabolism in humans. , 1998, Toxicology and applied pharmacology.

[60]  K M Lee,et al.  Physiologically based pharmacokinetic model for chronic inhalation of 2-butoxyethanol. , 1998, Toxicology and applied pharmacology.

[61]  Hugh A. Barton,et al.  Database for Physiologically Based Pharmacokinetic (PBPK) Modeling: Physiological Data for Healthy and Health-Impaired Elderly , 2009, Journal of toxicology and environmental health. Part B, Critical reviews.

[62]  Harvey J Clewell,et al.  Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling , 2007, Journal of Exposure Science and Environmental Epidemiology.

[63]  Melvin E Andersen,et al.  Dose-dependent transitions in mechanisms of toxicity. , 2004, Toxicology and applied pharmacology.

[64]  K. Krishnan,et al.  Quantitative structure-property relationships for interspecies extrapolation of the inhalation pharmacokinetics of organic chemicals. , 2005, Chemical research in toxicology.

[65]  H J Clewell,et al.  Sensitivity of physiologically based pharmacokinetic models to variation in model parameters: methylene chloride. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.

[66]  S. Majid Hassanizadeh,et al.  Model definition and model validation , 1994 .

[67]  E. V. Nieuwenhuyse.  Derivation of Assessment Factors for Human Health Risk Assessment , 2003 .

[68]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[69]  A. Renwick.  Data-derived safety factors for the evaluation of food additives and environmental contaminants. , 1993, Food additives and contaminants.

[70]  Harvey J Clewell,et al.  Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. , 2004, Toxicological sciences : an official journal of the Society of Toxicology.

[71]  F Y Bois,et al.  Statistical issues in toxicokinetic modeling: a bayesian perspective. , 2000, Environmental health perspectives.

[72]  H J Clewell,et al.  Investigation of the impact of pharmacokinetic variability and uncertainty on risks predicted with a pharmacokinetic model for chloroform. , 1996, Toxicology.

[73]  A M Jarabek,et al.  The application of dosimetry models to identify key processes and parameters for default dose-response assessment approaches. , 1995, Toxicology letters.

[74]  S. S. Iyengar,et al.  Statistical techniques in modeling of complex systems: Single and multiresponse models , 1983, IEEE Transactions on Systems, Man, and Cybernetics.

[75]  R. J. Lutz,et al.  A review of the applications of physiologically based pharmacokinetic modeling , 1979, Journal of Pharmacokinetics and Biopharmaceutics.

[76]  Hugh A Barton,et al.  Framework for Evaluation of Physiologically‐Based Pharmacokinetic Models for Use in Safety or Risk Assessment , 2004, Risk analysis : an official publication of the Society for Risk Analysis.

[77]  Andrew G. Renwick.  Subdivision of Uncertainty Factors to Allow for Toxicokinetics and Toxicodynamics , 1999 .

[78]  Ivelina Gueorguieva,et al.  Diazepam Pharamacokinetics from Preclinical to Phase I Using a Bayesian Population Physiologically Based Pharmacokinetic Model with Informative Prior Distributions in Winbugs , 2006, Journal of Pharmacokinetics and Pharmacodynamics.

[79]  L Finkelstein,et al.  Validation of simple and complex models in physiology and medicine. , 1984, The American journal of physiology.

[80]  F Y Bois,et al.  Applications of population approaches in toxicology. , 2001, Toxicology letters.

[81]  Paul S. Price,et al.  Defining the Interindividual (Intraspecies) Uncertainty Factor , 1999 .

[82]  Harvey J Clewell,et al.  Bayesian population analysis of a harmonized physiologically based pharmacokinetic model of trichloroethylene and its metabolites. , 2006, Regulatory toxicology and pharmacology : RTP.

[83]  E. Adolph,et al.  Quantitative Relations in the Physiological Constitutions of Mammals. , 1949, Science.

[84]  H. Barton,et al.  Predicting maternal rat and pup exposures: how different are they? , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[85]  Weihsueh A. Chiu,et al.  Pharmacokinetic/Physiologically Based Pharmacokinetic Models in Integrated Risk Information System Assessments , 2006 .

[86]  T. Maurer,et al.  Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery , 2002, Biopharmaceutics & drug disposition.

[87]  J. Pauluhn.  Issues of dosimetry in inhalation toxicity. , 2003, Toxicology letters.

[88]  W Slob,et al.  Assessment factors for human health risk assessment: a discussion paper. , 1999, Critical reviews in toxicology.

[89]  A. Gelman,et al.  Physiological Pharmacokinetic Analysis Using Population Modeling and Informative Prior Distributions , 1996 .

[90]  Aldo Rescigno,et al.  The use and abuse of models , 1987, Journal of Pharmacokinetics and Biopharmaceutics.

[91]  Melvin E Andersen,et al.  Toxicokinetic modeling and its applications in chemical risk assessment. , 2003, Toxicology letters.

[92]  D Hattis,et al.  Uncertainties in pharmacokinetic modeling for perchloroethylene: II. Comparison of model predictions with data for a variety of different parameters. , 1993, Risk analysis : an official publication of the Society for Risk Analysis.

[93]  Kannan Krishnan,et al.  Deriving Uncertainty Factors for Threshold Chemical Contaminants in Drinking Water , 2007, Journal of toxicology and environmental health. Part B, Critical reviews.

[94]  J. Molnar,et al.  Physiologically Based Pharmacokinetic Modeling???Science and Applications , 2006 .

[95]  Harvey J Clewell,et al.  Development and specification of physiologically based pharmacokinetic models for use in risk assessment. , 2008, Regulatory toxicology and pharmacology : RTP.

[96]  Kannan Krishnan,et al.  Physiological modeling and extrapolation of pharmacokinetic interactions from binary to more complex chemical mixtures. , 2002, Environmental health perspectives.

[97]  Torsten Teorell,et al.  Kinetics of distribution of substances administered to the body, II : The intravascular modes of administration , 1937 .

[98]  A. H. Marcus,et al.  Some useful statistical methods for model validation. , 1998, Environmental health perspectives.

[99]  J M Collins,et al.  Extrapolation of animal toxicity to humans: interspecies comparisons in drug development. , 1990, Regulatory toxicology and pharmacology : RTP.

[100]  R K Jain,et al.  Physiologically based pharmacokinetic modeling: principles and applications. , 1983, Journal of pharmaceutical sciences.

[101]  Jennifer Seed,et al.  A Framework for Human Relevance Analysis of Information on Carcinogenic Modes of Action , 2003, Critical reviews in toxicology.

[102]  Division on Earth.  Risk Assessment in the Federal Government: Managing the Process , 1983 .

[103]  M. Dellarco,et al.  From dermal exposure to internal dose , 2007, Journal of Exposure Science and Environmental Epidemiology.

[104]  Hugh A Barton,et al.  Approaches for Applications of Physiologically Based Pharmacokinetic Models in Risk Assessment , 2008, Journal of toxicology and environmental health. Part B, Critical reviews.

[105]  Tim Morris,et al.  Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.

[106]  Vincent C. Rideout,et al.  Mathematical and Computer Modeling of Physiological Systems , 1991 .

[107]  Melvin E Andersen,et al.  Tissue exposures to free and glucuronidated monobutylyphthalate in the pregnant and fetal rat following exposure to di-n-butylphthalate: evaluation with a PBPK model. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[108]  Walter Schmitt,et al.  Development of a Physiology-Based Whole-Body Population Model for Assessing the Influence of Individual Variability on the Pharmacokinetics of Drugs , 2007, Journal of Pharmacokinetics and Pharmacodynamics.

[109]  Ursula Gundert-Remy,et al.  The use of toxicokinetic and toxicodynamic data in risk assessment: an international perspective. , 2002, The Science of the total environment.

[110]  J. C. Helton,et al.  An Investigation of Uncertainty and Sensitivity Analysis Techniques for Computer Models , 1988 .

[111]  M L Dourson,et al.  Genetic polymorphisms in assessing interindividual variability in delivered dose. , 2002, Regulatory toxicology and pharmacology : RTP.